EE200200207A - Kinoliiniderivaatide kasutamine vähivastase ravimi valmistamiseks, ühendite saamine ning neid sisaldavad farmatseutilised kompositsioonid - Google Patents

Kinoliiniderivaatide kasutamine vähivastase ravimi valmistamiseks, ühendite saamine ning neid sisaldavad farmatseutilised kompositsioonid

Info

Publication number
EE200200207A
EE200200207A EEP200200207A EEP200200207A EE200200207A EE 200200207 A EE200200207 A EE 200200207A EE P200200207 A EEP200200207 A EE P200200207A EE P200200207 A EEP200200207 A EE P200200207A EE 200200207 A EE200200207 A EE 200200207A
Authority
EE
Estonia
Prior art keywords
preparation
compounds
pharmaceutical compositions
compositions containing
anticancer drug
Prior art date
Application number
EEP200200207A
Other languages
English (en)
Estonian (et)
Inventor
Hedlund Gunnar
Jansson Karl
J�nsson Stig
Bj�rk Anders
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9903838A external-priority patent/SE9903838D0/xx
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Publication of EE200200207A publication Critical patent/EE200200207A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EEP200200207A 1999-10-25 2000-10-24 Kinoliiniderivaatide kasutamine vähivastase ravimi valmistamiseks, ühendite saamine ning neid sisaldavad farmatseutilised kompositsioonid EE200200207A (et)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16140799P 1999-10-25 1999-10-25
SE9903838A SE9903838D0 (sv) 1999-10-25 1999-10-25 Novel compounds
US21281600P 2000-06-21 2000-06-21
SE0002320A SE0002320D0 (sv) 1999-10-25 2000-06-21 Malignant tumors
PCT/SE2000/002055 WO2001030758A1 (en) 1999-10-25 2000-10-24 Drugs for the treatment of malignant tumours

Publications (1)

Publication Number Publication Date
EE200200207A true EE200200207A (et) 2003-06-16

Family

ID=27484521

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200207A EE200200207A (et) 1999-10-25 2000-10-24 Kinoliiniderivaatide kasutamine vähivastase ravimi valmistamiseks, ühendite saamine ning neid sisaldavad farmatseutilised kompositsioonid

Country Status (21)

Country Link
EP (1) EP1224172B1 (de)
JP (1) JP3950337B2 (de)
KR (2) KR100674160B1 (de)
AT (1) ATE358668T1 (de)
AU (1) AU775057B2 (de)
CA (1) CA2386775C (de)
CZ (1) CZ298534B6 (de)
DE (1) DE60034240T2 (de)
DK (1) DK1224172T3 (de)
EE (1) EE200200207A (de)
ES (1) ES2280258T3 (de)
HK (1) HK1049830A1 (de)
HR (1) HRP20020353A2 (de)
HU (1) HU229072B1 (de)
IL (2) IL148782A0 (de)
IS (1) IS2750B (de)
NO (1) NO323320B1 (de)
NZ (1) NZ518296A (de)
SE (1) SE0002320D0 (de)
UA (1) UA73748C2 (de)
WO (1) WO2001030758A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314124B2 (en) 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
SE0400235D0 (sv) * 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
SE0401578D0 (sv) * 2004-06-18 2004-06-18 Active Biotech Ab Novel compounds
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
CN101891680B (zh) 2004-06-24 2014-10-29 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的调控剂
SG10201508623RA (en) 2005-10-19 2015-11-27 Teva Pharma Crystals of laquinimod sodium, and process for the manufacture thereof
DK3219705T3 (da) 2005-12-28 2020-04-14 Vertex Pharma Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid
KR20150065951A (ko) 2006-06-12 2015-06-15 테바 파마슈티컬 인더스트리즈 리미티드 안정한 라퀴니모드 제제
KR100916160B1 (ko) * 2007-02-21 2009-09-08 (주)바이오버드 약제학적 항암 조성물
EP2065380A1 (de) * 2007-08-22 2009-06-03 F.Hoffmann-La Roche Ag Pyridonamid-Derivate als Focal-Adhesion-Kinase (FAK) Hemmer und deren Verwendung zur Behandlung von Krebs
WO2009082471A1 (en) 2007-12-20 2009-07-02 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
MX2011002033A (es) 2008-09-03 2011-05-02 Teva Pharma 2-oxo-1,2-dihidro-quinolinas moduladoras de la funcion inmune.
KR101727762B1 (ko) 2009-03-20 2017-04-17 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 막횡단 전도도 조절자의 조정자의 제조 방법
KR20130065728A (ko) * 2010-10-14 2013-06-19 임뮤나르 에이비 Ahr 활성화제로서의 1,2-디히드로-4-히드록시-2-옥소-퀴놀린-3-카르복사닐리드
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
EP2537517A1 (de) 2011-06-22 2012-12-26 Active Biotech AB Deuterium-angereichertes 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluor-methyl)phenyl]-1,2-dihydrochinolin-3-carboxamid
JP2015511583A (ja) 2012-02-27 2015-04-20 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 薬学的組成物およびその投与
MX2015005632A (es) * 2012-11-07 2016-02-05 Teva Pharma Sales de amina de laquinimod.
EP2970129A2 (de) 2013-03-14 2016-01-20 Teva Pharmaceutical Industries Ltd. Kristalle aus laquinimodnatrium und verbessertes verfahren zur herstellung davon
WO2016042112A1 (en) 2014-09-23 2016-03-24 Active Biotech Ab Quinoline carboxamides for use in the treatment of multiple myeloma
CN107250113B (zh) 2014-10-07 2019-03-29 弗特克斯药品有限公司 囊性纤维化跨膜传导调节蛋白的调节剂的共晶
ES2663836T3 (es) 2014-11-19 2018-04-17 Active Biotech Ab Carboxamidas de quinolina para su uso en el tratamiento de leucemia
US11826363B2 (en) 2017-10-13 2023-11-28 Ono Pharmaceutical Co., Ltd. Therapeutic agent for solid cancers, which comprises Axl inhibitor as active ingredient
US12478621B2 (en) * 2019-11-28 2025-11-25 Deutsches Krebsforschungszentrum Substituted aminoquinolones as dgkalpha inhibitors for immune activation
CA3168070A1 (en) 2020-03-03 2021-09-10 Active Biotech Ab Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy
AU2021275994A1 (en) * 2020-05-21 2022-12-22 Stemsynergy Therapeutics, Inc. Notch inhibitors and uses thereof
PL4277628T3 (pl) 2021-01-18 2026-02-09 Active Biotech Ab Taskwinimod lub jego farmaceutycznie dopuszczalna sól do stosowania w leczeniu zespołu mielodysplastycznego
JP2024520307A (ja) 2021-05-25 2024-05-24 アクティブ バイオテック エイビー 複数のタスキニモド粒子およびその使用
JP2024524158A (ja) 2021-07-02 2024-07-05 アクティブ バイオテック エイビー タスキニモドを含有する医薬製品および前記製品の純度を評価する方法
AR126963A1 (es) 2021-09-13 2023-12-06 Lilly Co Eli Agonistas de ahr
TWI838849B (zh) 2021-09-13 2024-04-11 美商美國禮來大藥廠 Ahr促效劑
EP4452946A4 (de) * 2021-12-20 2025-11-26 Univ Johns Hopkins Verbindungen zur behandlung von krebs

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
GB9108547D0 (en) * 1991-04-22 1991-06-05 Fujisawa Pharmaceutical Co Quinoline derivatives
GB9404378D0 (en) * 1994-03-07 1994-04-20 Fujisawa Pharmaceutical Co Quinoline derivatives
GB2290786A (en) * 1994-06-30 1996-01-10 Fujisawa Pharmaceutical Co Quinoline derivatives
SE9801474D0 (sv) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
SE9802549D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
SE9802550D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6121287A (en) * 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives

Also Published As

Publication number Publication date
UA73748C2 (en) 2005-09-15
IL148782A0 (en) 2002-09-12
NO323320B1 (no) 2007-03-12
IS6329A (is) 2002-04-02
HUP0203238A2 (hu) 2003-01-28
CZ20021293A3 (cs) 2002-07-17
KR20060054496A (ko) 2006-05-22
NO20021932L (no) 2002-06-21
KR100597938B1 (ko) 2006-07-06
JP3950337B2 (ja) 2007-08-01
HUP0203238A3 (en) 2003-05-28
DE60034240T2 (de) 2007-12-20
CA2386775A1 (en) 2001-05-03
KR20020043646A (ko) 2002-06-10
AU775057B2 (en) 2004-07-15
NZ518296A (en) 2003-06-30
SE0002320D0 (sv) 2000-06-21
HRP20020353A2 (en) 2005-10-31
HU229072B1 (en) 2013-07-29
IL148782A (en) 2007-05-15
CZ298534B6 (cs) 2007-10-31
KR100674160B1 (ko) 2007-01-24
JP2003512454A (ja) 2003-04-02
AU1185101A (en) 2001-05-08
NO20021932D0 (no) 2002-04-24
EP1224172A1 (de) 2002-07-24
CA2386775C (en) 2004-07-13
DE60034240D1 (de) 2007-05-16
HK1049830A1 (zh) 2003-05-30
WO2001030758A1 (en) 2001-05-03
EP1224172B1 (de) 2007-04-04
ES2280258T3 (es) 2007-09-16
IS2750B (is) 2011-08-15
DK1224172T3 (da) 2007-08-13
ATE358668T1 (de) 2007-04-15

Similar Documents

Publication Publication Date Title
DE60034240D1 (de) Drogen zur behandlung maligner tumoren
YU23202A (sh) Lekovi za tretman malignih tumora
SE9904505D0 (sv) Novel compounds
DK1519724T3 (da) Fredericamycin-derivater som lægemidler til behandling af tumorer
ATE316083T1 (de) Adamantanderivate
SE0104140D0 (sv) Novel Compounds
AU2002218167A1 (en) N-phenyl-2-pyrimidine-amine derivatives
CY1109681T1 (el) Υποκατεστημενα παραγωγα κιναζολινης ως αναστολεις των κινασων aurora
DE60030741D1 (de) Chinazoline verbindungen als heilmittel
ATE309194T1 (de) Neuartige dicarbonsäurederivate mit pharmazeutischen eigenschaften
BRPI0519567A2 (pt) heterociclos tricÍclicos, sua fabricaÇço e uso como agentes farmacÊuticos
BR0112589A (pt) Derivados de heteroarila e sua aplicação como medicamento
WO2004018475A3 (en) Analogs of indole-3-carbinol metabolites as chemotherapeutic and chemopreventive agents
MY124146A (en) Novel 2-(iminomethyl) amino-phenyl derivatives, preparation, application as medicines and pharmaceutical compositions containing same
ATE233754T1 (de) Diphenyl-piperidin derivate
TR199900336T2 (xx) EAA antagonistleri olarak tetrahidrokinolin t�revleri.
ATE236147T1 (de) Derivate von flavonen, xanthonen und kumarinen
EP1678162A4 (de) P-glycoprotein-inhibitor, verfahren zu dessen herstellung und pharmazeutische zusammensetzung, die diesen enthält
DE60301339D1 (de) Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen
SE9902551D0 (sv) Novel compounds
NO20031410L (no) Anvendelse av distamycinderivater for fremstilling av medikamenter
MXPA03008801A (es) Aril oxima-piperazinas utiles como antagonistas de ccr5.
EE200200143A (et) 4-bensüülaminokinoliini konjugaadid sapphappega ja nende heteroanaloogid, nende valmistamismeetod ning neid ühendeid sisaldavad ravimid ja nende kasutamine
MY139613A (en) Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders
EP1428825A4 (de) Benzimidazolderivate